Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer
- 30 September 2006
- journal article
- Published by Elsevier BV in Urology
- Vol. 68 (3), 565-569
- https://doi.org/10.1016/j.urology.2006.03.055
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerThe New England Journal of Medicine, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerThe New England Journal of Medicine, 2004
- Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical ProstatectomyThe New England Journal of Medicine, 2004
- SURVIVAL OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN ERAJournal of Urology, 2004
- Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working GroupJournal of Clinical Oncology, 2004
- Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancerUrology, 2003
- Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)Urologic Oncology, 2003
- Determinants of Prostate Cancer–Specific Survival After Radiation Therapy for Patients With Clinically Localized Prostate CancerJournal of Clinical Oncology, 2002
- Prognostic Significance of The Nadir Prostate Specific Antigen Level After Hormone Therapy for Prostate CancerJournal of Urology, 2002
- Clinical Observations on the Doubling Time of Prostate CancerEuropean Urology, 1993